Method and composition for enhancing the cancer-treating efficacy of bacterial extracellular vesicles
Combining bacterial extracellular vesicles with immune checkpoint inhibitors addresses the variability in cancer treatment efficacy by enhancing therapeutic outcomes and minimizing side effects, leveraging the immune system's memory for sustained cancer treatment.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ブルー シード エクソソーム リミテッド
- Filing Date
- 2026-01-09
- Publication Date
- 2026-05-26
AI Technical Summary
Existing cancer treatments, particularly immune checkpoint inhibitors, exhibit varying efficacy among patients, and the mechanisms by which gut bacteria enhance their efficacy remain unclear, limiting their effectiveness in cancer therapy.
A method involving the co-administration of bacterial extracellular vesicles with immune checkpoint inhibitors, utilizing both Gram-negative and Gram-positive bacteria, to enhance cancer treatment efficacy by targeting immune checkpoints and promoting an anti-cancer immune response.
The combination of bacterial extracellular vesicles with immune checkpoint inhibitors demonstrates a synergistic effect, enhancing cancer treatment efficacy while reducing side effects, and providing a long-lasting therapeutic impact through the immune system's memory capabilities.
Smart Images
Figure 2026086412000001_ABST